Preview  24 Total

Sunday, June 23  19 Total

Using artificial intelligence to disrupt the VWF-GPIBα interaction in platelet-type von Willebrand disease

Using artificial intelligence to disrupt the VWF-GPIBα interaction in platelet-type von Willebrand disease

June 23, 2024 | Thomas David Daniel Kazmirchuk, Ph.D.; Carleton University; Ottawa, Canada
Use of global coagulation assays to predict spontaneous major bleeding in chronic kidney disease patients

Use of global coagulation assays to predict spontaneous major bleeding in chronic kidney disease patients

June 23, 2024 | Rowena Brook, M.B.B.S.; Northern Health; Melbourne, Australia


Novel FVIIIa-mimetic molecule with the potential to be the first oral treatment for severe hemophilia A

Novel FVIIIa-mimetic molecule with the potential to be the first oral treatment for severe hemophilia A

June 23, 2024 | Jacob Lund, Ph.D.; Novo Nordisk A/S; Bagsvaerd, Denmark
Canonical and non-canonical FXII functions synergistically drive ovarian cancer-associated thrombosis and tumor progression

Canonical and non-canonical FXII functions synergistically drive ovarian cancer-associated thrombosis and tumor progression

June 23, 2024 | Dillon Bohinc, B.S.; Case Western Reserve University; Cleveland, OH, U.S.
EMA601, a novel humanized fab inhibits platelet glycoprotein VI with unprecedented potency and protects mice from arterial thrombosis and ischemic stroke

EMA601, a novel humanized fab inhibits platelet glycoprotein VI with unprecedented potency and protects mice from arterial thrombosis and ischemic stroke

June 23, 2024 | Stefano Navarro, Ph.D.; University of Wuerzburg; Wuerzburg, Germany; and Bernhard Nieswandt, Ph.D.; University of Wuerzburg and Emfret Analytics GmbH; Wuerzburg, Germany; Eibelstadt Germany
Fibrinogenγ390-396A protects against high fat diet-induced obesity and MASLD by altering glycine metabolism

Fibrinogenγ390-396A protects against high fat diet-induced obesity and MASLD by altering glycine metabolism

June 23, 2024 | Woosuk Steve Hur, Ph.D.; University of North Carolina at Chapel Hill; Chapel Hill, NC, U.S.

Evaluation of recombinant human prourokinase in the treatment of acute pulmonary embolism (ERUPTE): a randomized single-blinded multicenter phase 2 trial

Evaluation of recombinant human prourokinase in the treatment of acute pulmonary embolism (ERUPTE): a randomized single-blinded multicenter phase 2 trial

June 23, 2024 | Zhi-Cheng Jing, M.D.; Guangdong Provincial People's Hospital; Guangzhou, China; and Chun-Yan Cheng, M.D., Ph.D.; Guangdong Provincial People's Hospital; Guangzhou, China

Tuesday, June 25  0 Total

Wednesday, June 26  0 Total